Biggest News Aggregation in the World
๐Ÿ“ฐ Advanced Solid Tumors News

Page 3 - Advanced Solid Tumors News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Advanced Solid Tumors. Real-time updates on events, politics, business and more.

Kirtane Highlights Uniqueness of Solid Tumor CAR T-Cell Agent A2B530

Kedar Kirtane, MD, speaks on the unique mechanism of action of A2B530 and how the agent could represent a huge leap forward in the application of CAR T-cell agents for patients with solid tumors if the EVEREST-1 study proves to be positive.
United States Kedar Kirtane Endocrine Oncology At Moffitt Cancer Center Department Of Head Neck Endocrine Oncology Moffitt Cancer Center

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Evaxion's AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial

Evaxion Biotech A/S (NASDAQ: EVAX) (โ€œEvaxionโ€ or the โ€œCompanyโ€), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today presented promising clinical data from its EVX-01 Phase 1 dose escalation trial in metastatic melanoma at the 2023 ASCO annual meeting in ...
United States Neopepvac Clinicaltrials Per Norl Chief Executive Officer Neo Antigen Vaccine Advanced Solid Tumors

Daiichi Sankyo : ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid Tumors(414.1KB

Press Release ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid Tumors ... | June 5, 2023
United States Mark Rutstein Daiichi Sankyo Cristian Massacesi Oncology Development University Of Texas Md Anderson Cancer Center

Evaxion Biotech: Evaxion's AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial

The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerabilityPositive clinical responses were reported in 8 out of 12 EVX-01 treated patientsHigh-quality
United States Securities Exchange Exchange Commission Per Norl Chief Executive Officer Neo Antigen Vaccine

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science